Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease

The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and

Saved in:
Bibliographic Details
Published in:Cancer discovery 2021-02, Vol.11 (2), p.308-325
Main Authors: Catenacci, Daniel V T, Moya, Stephanie, Lomnicki, Samantha, Chase, Leah M, Peterson, Bryan F, Reizine, Natalie, Alpert, Lindsay, Setia, Namrata, Xiao, Shu-Yuan, Hart, John, Siddiqui, Uzma D, Hogarth, D Kyle, Eng, Oliver S, Turaga, Kiran, Roggin, Kevin, Posner, Mitchell C, Chang, Paul, Narula, Sunil, Rampurwala, Murtuza, Ji, Yuan, Karrison, Theodore, Liao, Chih-Yi, Polite, Blase N, Kindler, Hedy L
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - secondary
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - therapeutic use
Chicago
Esophageal Neoplasms - drug therapy
Esophageal Neoplasms - pathology
Female
Humans
Male
Middle Aged
Molecular Targeted Therapy
Progression-Free Survival
Stomach Neoplasms - drug therapy
Stomach Neoplasms - pathology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The one-year and median overall survival (mOS) rates of advanced gastroesophageal adenocarcinomas (GEA) are ∼50% and
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-20-1408